Related Experiment Video
Updated: Apr 18, 2026
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Protection of MPTP-induced neuroinflammation and neurodegeneration by rotigotine-loaded microspheres
Xin Yu1, Jun-Yi Yao1, Jie He2
1School of Pharmacy, Yantai University, Yantai 264005, PR China.
Aims:
The aim of the study is to evaluate the neuroprotective effects of continuous dopaminergic stimulation (CDS) by rotigotine-loaded microspheres (RoMS) in a mouse model of MPTP-induced Parkinson's disease (PD) and to elucidate the potential mechanism underlying these effects.
Main Methods:
Male C57BL/6 mice were treated either intramuscularly once with RoMS or twice daily for two weeks with rotigotine, and from the 9th day, MPTP (30 mg/kg, i.p.) was injected for the last 5 days. Following treatment, Parkinsonism scores were calculated and oxidative stress-related indicators in the striatum were performed. Neuroinflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) were detected in the striatum. Expression of apoptosis-related proteins B-cell leukemia/lymphoma 2 (Bcl-2) and Bcl-2-associated X protein (BAX) was measured in the striatum by Western blot. Nigral tyrosine hydroxylase (TH)-positive neurons and microglial cell markers, i.e., ionized calcium binding adaptor molecule-1 (Iba-1) and neuronal synaptosomes, were quantified to assess the neuroprotective efficacy of RoMS.
Key Findings:
The administration of rotigotine significantly improved the Parkinsonism score, protected dopaminergic neurons with antioxidants, reduced microglial cell activation and the release of neuroinflammatory cytokines, and balanced the expression of Bcl-2 and Bax in MPTP-treated mice. Interestingly, the neuroprotective properties of rotigotine were remarkably amplified by CDS treatment with RoMS.
Significance:
These results suggest that CDS therapy can play a neuroprotective role in an MPTP mouse model. Neuroprotective disease-modifying therapy may have the potential benefits of early treatment by normalizing compensatory mechanisms and may also help to delay dyskinesia in the later stages of PD.
Insights
Continuous dopaminergic stimulation (CDS) with rotigotine-loaded microspheres (RoMS) demonstrated significant neuroprotection in a Parkinson
Area of Science:
- Neuroscience
- Pharmacology
- Neurodegenerative Diseases
Background:
- Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons.
- Current treatments primarily manage symptoms but do not halt disease progression.
- Continuous dopaminergic stimulation (CDS) is a therapeutic strategy aimed at providing more stable receptor activation.
Purpose of the Study:
- To evaluate the neuroprotective effects of continuous dopaminergic stimulation (CDS) using rotigotine-loaded microspheres (RoMS) in a mouse model of Parkinson's disease (PD) induced by MPTP.
- To investigate the underlying mechanisms of neuroprotection offered by RoMS, including effects on oxidative stress, neuroinflammation, and apoptosis.
- To assess the efficacy of RoMS in improving motor deficits and preserving dopaminergic neurons.
Main Methods:
- Male C57BL/6 mice were administered either RoMS (intramuscularly once) or rotigotine (twice daily for two weeks).
- MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) was administered to induce Parkinsonism.
- Evaluated outcomes included motor function (Parkinsonism scores), striatal oxidative stress markers, neuroinflammatory cytokines (TNF-α, IL-1β, IL-6), apoptosis-related proteins (Bcl-2, BAX), dopaminergic neuron survival (TH-positive neurons), and microglial activation (Iba-1).
Main Results:
- Rotigotine administration significantly improved Parkinsonism scores and protected dopaminergic neurons.
- Treatment reduced oxidative stress, microglial activation, and neuroinflammatory cytokine release in the striatum.
- RoMS administration amplified the neuroprotective effects of rotigotine, further balancing Bcl-2/BAX expression and preserving neuronal integrity.
Conclusions:
- Continuous dopaminergic stimulation (CDS) via RoMS exhibits significant neuroprotective effects in an MPTP-induced Parkinson's disease mouse model.
- This neuroprotective and potentially disease-modifying therapy may offer benefits in early PD treatment by normalizing compensatory mechanisms.
- CDS therapy holds promise for delaying motor complications, such as dyskinesia, in later stages of Parkinson's disease.
